Tarcocimab tedromer is under clinical development by Kodiak Sciences and currently in Phase III for Non-Proliferative Diabetic Retinopathy (NPDR). According to GlobalData, Phase III drugs for Non-Proliferative Diabetic Retinopathy (NPDR) have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Tarcocimab tedromer’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tarcocimab tedromer overview
Tarcocimab tedromer is under development for the treatment of non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, wet age-related macular degeneration (AMD) and macular edema due to retinal vein occlusion. It is administered through the intravitreal route. It acts by targeting vascular endothelial growth factor (VEGF). The drug candidate is a bioconjugate comprising two components. The first component is a recombinant, full-length humanized anti-VEGF monoclonal antibody, the second component is a branched, optically clear phosphorylcholine biopolymer which is stably attached to the antibody and which is intended to augment the stability and residence time of the bioconjugate in the eye without compromising its anti-VEGF activity. It is developed based on the high science antibody biopolymer conjugate (ABC) platform.
The drug candidate was development for the treatment of proliferative diabetic retinopathy, wet age-related macular degeneration (AMD), diabetic macular edema and macular edema due to retinal vein occlusion.
Kodiak Sciences overview
Kodiak Sciences is a biopharmaceutical company that develops and transformative therapeutics to treat retinal diseases. Its pipeline products includes tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer, which treats wet age-related macular degeneration (AMD); KSI-501, a bispecific conjugate for pro-inflammatory cytokine interleukin-6 (IL-6) and anti-vascular endothelial growth factor (VEGF) and KSI-101, unconjugated bispecific protein that targets interleukin-6 (IL-6) and anti-vascular endothelial growth factor (VEGF) developed for retinal inflammatory conditions. Kodiak Sciences is headquartered in Palo Alto, California, the US.
For a complete picture of Tarcocimab tedromer’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.